Principal Financial Group Inc. cut its position in shares of Catalent, Inc. (NYSE:CTLT – Get Rating) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 217,643 shares of the company’s stock after selling 4,742 shares during the period. Principal Financial Group Inc. owned approximately 0.12% of Catalent worth $9,796,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of the company. Cetera Advisor Networks LLC increased its position in shares of Catalent by 7.1% during the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock valued at $217,000 after acquiring an additional 130 shares during the last quarter. Mackay Shields LLC increased its position in shares of Catalent by 0.6% during the first quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock valued at $2,856,000 after acquiring an additional 149 shares during the last quarter. Texas Permanent School Fund increased its position in shares of Catalent by 0.8% during the fourth quarter. Texas Permanent School Fund now owns 25,569 shares of the company’s stock valued at $1,151,000 after acquiring an additional 212 shares during the last quarter. Global Strategic Investment Solutions LLC increased its position in shares of Catalent by 3.4% during the fourth quarter. Global Strategic Investment Solutions LLC now owns 6,937 shares of the company’s stock valued at $312,000 after acquiring an additional 229 shares during the last quarter. Finally, Czech National Bank increased its position in shares of Catalent by 1.1% during the fourth quarter. Czech National Bank now owns 21,065 shares of the company’s stock valued at $948,000 after acquiring an additional 238 shares during the last quarter. 99.38% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, SVP Mario Gargiulo sold 678 shares of the stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $33,805.08. Following the transaction, the senior vice president now directly owns 5,676 shares of the company’s stock, valued at approximately $283,005.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Manja Boerman sold 1,446 shares of the business’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $72,097.56. Following the completion of the sale, the insider now directly owns 14,414 shares of the company’s stock, valued at $718,682.04. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Mario Gargiulo sold 678 shares of the business’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $33,805.08. Following the completion of the sale, the senior vice president now directly owns 5,676 shares of the company’s stock, valued at $283,005.36. The disclosure for this sale can be found here. 0.58% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
CTLT has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Catalent from $29.00 to $37.00 in a research report on Monday, May 22nd. JPMorgan Chase & Co. cut shares of Catalent from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $90.00 to $45.00 in a report on Sunday, May 21st. Royal Bank of Canada dropped their price objective on shares of Catalent from $58.00 to $41.00 in a report on Monday, May 8th. Barclays dropped their price objective on shares of Catalent from $40.00 to $35.00 in a report on Sunday, May 21st. Finally, Robert W. Baird dropped their price objective on shares of Catalent from $53.00 to $35.00 in a report on Monday, May 22nd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Catalent currently has a consensus rating of “Hold” and a consensus price target of $67.55.
Catalent Trading Up 0.7 %
NYSE CTLT opened at $37.12 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.91 and a debt-to-equity ratio of 0.86. Catalent, Inc. has a 52 week low of $31.45 and a 52 week high of $115.33. The stock has a market capitalization of $6.68 billion, a PE ratio of 16.42, a price-to-earnings-growth ratio of 5.32 and a beta of 1.17. The firm has a 50 day moving average of $49.94 and a two-hundred day moving average of $52.77.
Catalent Profile
(Get Rating)
Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Further Reading
Receive News & Ratings for Catalent Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Catalent and related companies with MarketBeat.com’s FREE daily email newsletter.